How Rapid Therapeutic Evolution Has Complicated RCC Sequencing

This segment focuses on the growing complexity of treatment sequencing in advanced RCC as therapeutic options have expanded. The discussion emphasizes that while modern frontline regimens can produce meaningful responses, most patients will eventually require second-line therapy due to disease progression or acquired resistance. Dr. Voss highlights that the increasing number of available therapies has made it more difficult to determine optimal sequencing strategies. Clinicians must now anticipate future treatment needs when making initial decisions, rather than following a straightforward, linear approach. The speakers underscore that effective second-line options are critical, particularly in the immunotherapy-refractory setting, where clinical guidance remains limited. This segment reinforces the importance of understanding how earlier treatment choices influence subsequent therapy options and outcomes, and it highlights the need for continued research to define best practices in sequencing for patients with advanced RCC.